Clinical trials: HSIL, High Grade Squamous Intraepithelial Lesions
- Condition HSIL, High Grade Squamous Intraepithelial Lesions
- Funder type Industry (pharma, biotech, devices)
High-grade Squamous Intraepithelial Lesions (HSIL)
A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL
This study is intented to evaluate the safety, and tolerability and preliminary efficacy of Instantaneous CRISPR/Cas9 Gene Editing Therapy (BD114 virus-like particle, also BD114) for the treatment of high-grade squamous…
- Trial name
- NCT07170254
- Testing
- BD114VLP, or BD114
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
High-grade Squamous Intraepithelial Lesion (HSIL)
NWRD08 DNA Plasmid for HPV-16 and/or HPV-18 Related Cervical HSIL
This is a single-arm, open label, multi-center Phase 1 clinical study to evaluate the safety and tolerability of HPV-16 and HPV-18-targeted DNA plasmid vaccine (NWRD08) in patients HPV-16 and/or HPV-18 related cervical HSIL.
- Trial name
- NCT06276101
- Testing
- NWRD08 administered by electroporation
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
High-grade Squamous Intraepithelial Lesion (HSIL)
NWRD09 for HPV-16 Related Cervical HSIL
This is a single-arm, open label, multi-center clinical study to evaluate the safety, tolerability and immunogenicity HPV16 targeted mRNA therapeutic vaccine (NWRD09) in HPV16 related cervical high-grade squamous intraepithelial…
- Trial name
- NCT07047989
- Testing
- NWRD09 injection
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Newish Biotech (Wuxi) Co., Ltd.
Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL
Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants
This is a phase II double blind, placebo-controlled, randomized study of artesunate ointment for the treatment of HIV-negative men and women who have anal high grade squamous intraepithelial lesions (anal HSIL)
- Conditions
- Anal High-grade Squamous Intraepithelial Lesion, Anal HSIL, Anal HPV Infection, AIN
- Trial name
- ART-AIN IIB-2 (NCT06206564)
- Testing
- Artesunate ointment
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Frantz Viral Therapeutics, LLC